Abstract: A video encoding/decoding apparatus according to the present invention acquires motion vector refinement information, performs motion compensation on the basis of a motion vector of a current block, refines the motion vector of the current block using at least one or both of the motion vector refinement information and the output of the motion compensation, and performs motion compensation using the refined motion vector.

Abstract: A pharmaceutical composition or a health functional food including a macrolide compound, a method of preparing the same, and a method using the same may be used to prevent or treat Mycobacterium sp. bacterial infection, such as tuberculosis, Hansen's disease, and non-tuberculous Mycobacterium sp. bacterial infections, or symptoms related thereto.

Abstract: Provided are novel piperazic acid containing peptide compound stereoisomer, solvate, or pharmaceutically acceptable salt thereof, method of preparing the same, and use thereof. The peptide compound, stereoisomer, solvate, or pharmaceutically acceptable salt thereof has activities of anticancer, anti-metastasis, and growth inhibition of resistant tumors, and thus may be used to prevent or treat various cancers or metastases of cancer.

Abstract: Provided are a novel tricyclic dilactone compound, a strain producing the same, a method of producing the tricyclic dilactone compound, and use of the tricyclic dilactone compound. The tricyclic dilactone compound has activity of inhibiting aggregation of amyloid-beta and tau proteins, activity of inhibiting apoptosis, and anti-inflammation activity, and thus may be used to prevent, treat, or improve various neurodegenerative brain diseases including Alzheimer's disease and cognitive impairment.

Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.

Abstract: Provided are a pharmaceutical composition for preventing or treating Mycobacterium sp. infection or a related symptom thereof, wherein the pharmaceutical composition includes a compound including a peptide represented by Formula 1, or an isomer, a derivative, a solvate, or a pharmaceutically acceptable salt thereof; and a method using the same. The pharmaceutical composition has anti-Mycobacterium tuberculosis activity against Mycobacteria, e.g., Mycobacterium tuberculosis, and palliates inflammatory response caused by Mycobacterium tuberculosis. Thus, the pharmaceutical composition may be used in preventing or treating Mycobacterium sp. infection or a related symptom thereof.

Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.

Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.

Abstract: Provided are a pharmaceutical composition for preventing or treating Mycobacterium sp. infection or a related symptom thereof, wherein the pharmaceutical composition includes a compound including a peptide represented by Formula 1, or an isomer, a derivative, a solvate, or a pharmaceutically acceptable salt thereof; and a method using the same. The pharmaceutical composition has anti-Mycobacterium tuberculosis activity against Mycobacteria, e.g., Mycobacterium tuberculosis, and palliates inflammatory response caused by Mycobacterium tuberculosis. Thus, the pharmaceutical composition may be used in preventing or treating Mycobacterium sp. infection or a related symptom thereof.

Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.

Abstract: Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase.

Abstract: A resource allocation method and an apparatus for mitigating inter-cell interference in the heterogeneous cellular communication system are provided. The method for a first type base station to allocate resource in a wireless communication system including the first and second types base stations according to the present invention includes estimating an available Frequency Assignment (FA) not used by a neighbor second type terminal among FAs used by the first type base station, and allocating sub-channels associated with one of the available FAs not used by the neighbor second type terminal to a first type terminal, wherein the second type base station allocates the sub-channels for uplink and downlink transmissions of the second type terminal over a predetermined time period such that an FA in which sub-channels for the uplink transmissions are allocated and the FA in which sub-channels for the downlink transmissions are allocated are the same.

Abstract: Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase.

Abstract: A resource allocation method and an apparatus for mitigating inter-cell interference in the heterogeneous cellular communication system are provided. The method for a first type base station to allocate resource in a wireless communication system including the first and second types base stations according to the present invention includes estimating an available Frequency Assignment (FA) not used by a neighbor second type terminal among FAs used by the first type base station, and allocating sub-channels associated with one of the available FAs not used by the neighbor second type terminal to a first type terminal, wherein the second type base station allocates the sub-channels for uplink and downlink transmissions of the second type terminal over a predetermined time period such that an FA in which sub-channels for the uplink transmissions are allocated and the FA in which sub-channels for the downlink transmissions are allocated are the same.